论文部分内容阅读
报告用胎儿胸腺细胞悬液移植注射防治内源性哮喘患儿３４例。结果：治愈６７．６５％，显效２６．４７％，有效２．９４％，与胸腺素组（治愈６０％，显效２２．８６％，有效１１．４３％）比较无显著性差异（Ｐ＞０．０５），与常规治疗组（治愈０％，显效２５％，有效４０．６３％）比较总有效率和治愈率均有非常显著性差异（Ｐ＜０．０１）。患儿ＣＤ＿３、ＣＤ＿８明显低于正常对照组（Ｐ＜０．０１），ＣＤ＿４轻微升高（但Ｐ＞０．０５）．ＣＤ＿４／ＣＤ＿８明显高于正常对照组（Ｐ＜０．０１），提示患儿存在细胞免疫功能不全和免疫调节紊乱。经胎儿胸腺治疗后３个月患儿细胞免疫功能恢复正常，与正常对照组比较Ｐ＞０．０５。这些结果提示：胎儿胸腺具有调节机体细胞免疫功能，防治内源性哮喘反复发作的作用，且方法简单、安全，可作临床上一种防治手段。
Thirty-four children with endogenous asthma were reported with fetal thymocyte suspension injection. Results: 67.65% cured, effective 26.47%, effective 2.94%, no significant difference compared with thymosin group (cured 60%, effective 22.86%, effective 11.43%) (P> 0 .05). Compared with the conventional treatment group (0% cured, 25% effective, 40.63% effective), the total effective rate and the cure rate were significantly different (P <0.01). Children with CD_3, CD_8 were significantly lower than the normal control group (P <0.01), CD_4 slightly increased (but P> 0.05). CD_4 / CD_8 was significantly higher than the normal control group (P <0.01), suggesting that children with cellular immune dysfunction and immune disorders. Three months after fetal thymus treatment, cellular immune function returned to normal, compared with the normal control group P> 0.05. These results suggest that the fetal thymus has the function of regulating the cellular immunity of the body and preventing and treating the recurrence of endogenous asthma. The method is simple and safe and can be used as a kind of prevention and treatment in clinic.